Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-09-11FDA Approved: LENALIDOMIDE — Original Application (Novugen Pharma (USA) LLC)
FDA approved the original application for lenalidomide from Novugen Pharma (USA) LLC, enabling a generic version of the cancer drug lenalido…
-
CLINICAL_TRIALS research · 2024-09-04Clinical Trial Update: A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma [Phase 2]
A multicenter Phase II clinical trial evaluating zanubrutinib as maintenance therapy in patients with mantle cell lymphoma is currently recr…
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial from Memorial Sloan Kettering tested sequential chemotherapy and lenalidomide followed by rituximab and lenalidomid…
-
FDA approval · 2024-08-26FDA Approved: BORUZU — Original Application (Amneal Pharmaceuticals LLC)
FDA approved BORUZU (bortezomib) from Amneal Pharmaceuticals as an original NDA. The approval covers indications including multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab [Phase 3]
A Phase 3 randomized trial comparing bendamustine plus rituximab versus fludarabine plus rituximab in non-Hodgkin's lymphoma and mantle cell…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
This clinical trial update from Adaptive Biotechnologies aims to optimize ctDNA-based minimal residual disease assessment in patients with f…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas [Phase 3]
This Phase 3 trial update discusses how the duration of rituximab maintenance therapy may affect outcomes in various non-Hodgkin lymphomas, …
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) [Phase 1]
The ENABLE-1 Phase 1 trial investigates Toll-like receptor signaling to enhance B-cell lymphoma CAR-T therapy, with the study currently list…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]
Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multipl…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial at Peter MacCallum Cancer Centre is evaluating a venetoclax-ibrutinib-rituximab regimen with optional navitoclax for relapsed/…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
Phase 2 study evaluating a regimen of obinutuzumab, zanubrutinib, and lenalidomide, followed by a short cycle of obinutuzumab and cytarabine…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 [Phase 2]
This Phase 2 trial update reports long-term follow-up data and thalidomide maintenance outcomes for patients enrolled in Clinical Trial 2003…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR [Phase 1, Phase 2]
A Phase 1/2 clinical trial at University Hospital Heidelberg is evaluating third-generation CD19-directed CAR T cells in relapsed or refract…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL [Phase 1, Phase 2]
Mustang Bio's MB-106 study in relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia has been terminated, covering Phase 1…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) [Phase 2]
Phase 2 clinical trial update on LOXO-305 (pirtobrutinib) in Chinese participants with B-cell malignancies, with results posted on July 16, …
-
CLINICAL_TRIALS withdrawal · 2024-07-12Clinical Trial Update: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating Interferon-Beta-1a (FP-1201) to prevent toxicities after CD19-directed CAR T-cell therapy has been withdr…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment [Phase 3]
A Phase 3 trial is evaluating bendamustine and rituximab with or without orelabrutinib in mantle cell lymphoma. The study is currently recru…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma [NA]
This document provides an update on a clinical trial evaluating whole-body diffusion-weighted MRI for staging and predicting treatment respo…
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating a CAR-T cell therapy for untreated high-risk mantle cell lymphoma and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]
Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.